1. TGF-β1 modulates extracellular matrix–mediated MT1-MMP expression.
TGF-β1 modulates extracellular matrix–mediated MT1-MMP expression. A, HPDE cells plated onto plastic culture plates were treated with TGF-β1 (10 ng/mL) in the presence or absence of TβRI kinase inhibitor (TbRi, 5 μmol/L) for 24 hours. Cell lysates were analyzed for the 55-kDa active form of MT1-MMP (top) and ERK2 (bottom) by Western blotting. B, extracellular matrices deposited by HPDE cells, Panc1 cells, and pancreatic F5 fibroblasts were generated as described in Materials and Methods. HPDE cells were plated in the presence or absence of TβRI kinase inhibitor (TbRi, 5 μmol/L) for 24 hours onto its own matrix, Panc1 matrix, or F5 fibroblast matrix. Cell lysates were analyzed for the 55-kDa active form of MT1-MMP (top) and ERK2 (bottom) protein expression by Western blotting. C, HPDE cells were plated onto its own matrix or onto Panc1 or F5 fibroblast matrix and allowed to condition the media for 24 hours. The cell lysates were analyzed for TGF-β1 (top) and GAPDH (bottom) mRNA expression by RT-PCR and the conditioned media for total TGF-β1 by ELISA. *, P < 0.05, significantly different from control HPDE matrix. Representative of three different experiments.
Adam J. Ottaviano et al. Cancer Res 2006;66:
©2006 by American Association for Cancer Research